Jeffrey Siegel, MD
Office Director, Office of Drug Evaluation Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, USA
Jeffrey Siegel, M.D. is Office Director of the Office of Drug Evaluation Sciences at FDA. Previously Dr. Siegel was Executive Director, Head - Translational Medicine in the Clinical Research, Inflammation group at Gilead Sciences from March 2019 through December 2020. Before that, Dr. Siegel was Senior Group Medical Director, Global Head of Rheumatology & Rare Diseases in Product Development Immunology at Genentech / Roche from 2010-2019. While at Genentech/Roche, his group initiated and completed a Phase 2 and Phase 3 program for tocilizumab (Actemra) for systemic sclerosis, achieved 2 Breakthrough Therapy Designations and filed 2 sBLA's - both approved - and achieved 2 orphan drug designations.
Dr. Siegel received his medical degree from Yale University School of Medicine, internship and residency training at the University Hospitals of Cleveland, clinical fellowship training in Rheumatology at University Hospitals of Cleveland and basic science research training at the NIH in Immunology and signal transduction. After fellowship, he joined the Naval Medical Research Institute for 5 years where he served as Branch Head, Signal Transduction. He then joined the FDA and was there for 14 years, serving as Supervisory Medical Officer, Clinical Team Leader in Rheumatology.
He has received the Spirit of Leadership Award - Scleroderma Foundation Honors Genentech, and the PD Breakthrough Award - Therapy Designation Awarded to Roche for SSc Treatment.